• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » More evidence that antipsychotics are dangerous in dementia

More evidence that antipsychotics are dangerous in dementia

July 1, 2007
Jesse H. Wright, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Jesse H. Wright, MD. Professor and Chief of Adult Psychiatry, University of Louisville School of Medicine, Co-author, Learning Cognitive Behavior Therapy: An Illustrated Guide.

Dr. Wright has disclosed that he receives royalities from books he has written about cognitive behavioral therapy.

Subject:
Antipsychotics

Short Description:
More evidence that antipsychotics are dangerous in dementia

Background:
In 2005, the FDA issued a health advisory saying that antipsychotics appear to increase the risk of death in elderly patients with dementia. That advisory was based on data from placebo-controlled trials of antipsychotics conducted by industry. Now, a new study based on a completely different, and much larger, dataset, appears to confirm these dangers. Researchers used comprehensive medical records available through Canada’s health system to identify all elderly patients treated for dementia from 1997 to 2002 in the province of Ontario. A total of 27,259 patient records were examined. The researchers found that after 30 days of taking atypical antipsychotics, patients had a mortality rate of 3.9%, while matched patients on no antipsychotics had a mortality rate of 2.7%, meaning that atypicals increased the risk of early death by a factor of 1.55. Researchers had enough data to compare conventional agents vs. atypicals, and found that conventionals were riskier than atypicals by a factor of about 1.25 (Gill SS et al., Ann Intern Med 2007;146:775-786).

TCPR's Take:
The relative risk looks large, but the absolute risk is only 1.2%, meaning that atypicals would cause roughly one excess death out of each 100 patients treated with atypicals. The question is whether this small risk is overshadowed by the quality-of-life benefit agitated patients derive from being on antipsychotics. Many would argue that antipsychotics are worth this risk.

For more on this topic, see The Carlat Geriatric Psychiatry Report.

General Psychiatry
KEYWORDS antipsychotics dementia geriatric psychiatry
    Jesse H. Wright, MD

    Latest CATIE results: Atypicals no better than Trilafon for improving cognition

    More from this author
    www.thecarlatreport.com
    Issue Date: July 1, 2007
    SUBSCRIBE NOW
    Table Of Contents
    Does Psychotherapy Work?
    Psychotherapy: A Practical and Integrative Approach
    High Yield Cognitive-Behavior Therapy Techniques
    Zoloft not helpful for subsyndromal symptoms in cancer patients
    More evidence that antipsychotics are dangerous in dementia
    Is divorce a risk factor for getting a stimulant prescription?
    Latest CATIE results: Atypicals no better than Trilafon for improving cognition
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.